TP53 is associated with the resistance of cytotoxic treatment and patient prognosis, and the mutation rate of TP53 in esophageal squamous cell carcinoma (ESCC) is extraordinarily high, at over 90%. PRIMA-1 (p53 re-activation and induction of massive apoptosis) has recently been reported to restore the function of mutant TP53; however, its antitumor effect and mechanism in ESCC remain unclear. After evaluat- 
TP53 is associated with the resistance of cytotoxic treatment and patient prognosis, and the mutation rate of TP53 in esophageal squamous cell carcinoma (ESCC) is extraordinarily high, at over 90%. PRIMA-1 (p53 re-activation and induction of massive apoptosis) has recently been reported to restore the function of mutant TP53; however, its antitumor effect and mechanism in ESCC remain unclear. After evaluating the TP53 mutation status of a panel of 11 ESCC cell lines by Sanger sequencing, we assessed the in vitro effect of PRIMA-1 administration on cells with different TP53 status by conducting cell viability and apoptosis assays. The expression levels of proteins in p53-related pathways were examined by Western blotting, while knockdown studies were conducted to investigate the mechanism underlying PRIMA-1's function. An ESCC xenograft model was further used to evaluate the therapeutic effect of PRIMA-1 in vivo. PRIMA-1 markedly inhibited cell growth and induced apoptosis by upregulating Noxa expression in ESCC cell lines with TP53 missense mutations, whereas no apoptosis was induced in ESCC with wild-type TP53 and TP53 with frameshift and nonsense mutations. Importantly, the knockdown of Noxa canceled the apoptosis induced by PRIMA treatment in ESCC cell lines with TP53 missense mutations. PRIMA-1 administration, compared with placebo, showed a significant antitumor effect by inducing Noxa in the xenograft model of an ESCC cell line with a TP53 missense mutation. PRIMA-1 exhibits a significant antitumor effect, inducing massive apoptosis through the upregulation of Noxa in ESCC with TP53 missense mutations.
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| INTRODUCTION
Esophageal squamous cell carcinoma (ESCC) is one of the most malignant gastrointestinal cancers and is a leading cause of cancer death. 1, 2 Recently, advances in multimodal treatments (ie, preoperative chemotherapy or chemo-radiotherapy followed by surgery) have improved the clinical outcomes of locally advanced ESCC to some extent; however, the survival benefit is generally confined to
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responders to these treatments. [3] [4] [5] [6] Therefore, the development of a novel promising therapy targeting specific molecules is indispensable to improve the prognosis of ESCC patients.
TP53 is a well-known tumor suppressor gene that induces apoptosis, cell cycle arrest, senescence, DNA repair or autophagy under stress conditions. [7] [8] [9] [10] However, mutant TP53 is known to lose tumor suppressor functions and is associated with tumor malignancy, including invasion, metastasis or resistance to cytotoxic treatments. [11] [12] [13] The mutation rate of TP53 is reported to be 30%-50% in several types of cancer, including multiple myeloma, breast cancer, colorectal cancer and prostate cancer. [14] [15] [16] [17] Notably, the TP53 mutation rate of ESCC has been identified to be extraordinarily high, at over 90%. 18, 19 In fact, some previous studies have shown that mutation of TP53 is associated with patient prognosis, carcinogenesis, and resistance to chemotherapy or chemo-radiotherapy in ESCC. [20] [21] [22] [23] Therefore, therapeutic strategies targeting mutant TP53 which most ESCC carry may be a promising approach to the improvement of prognosis in ESCC patients.
PRIMA-1 (p53 re-activation and induction of massive apoptosis), a low molecular weight compound, has been recently reported to restore the function of wild-type TP53 to mutant TP53 and to induce p53-mediated apoptosis. 24 The anticancer effects of PRIMA- 30 However, to the best of our knowledge, the treatment effect of PRIMA-1 and its mechanism in ESCC have never been investigated. This study was designed to assess the antitumor effect of PRIMA-1 treatment in both a panel of ESCC cell lines with different TP53 status and an ESCC xenograft model and to uncover the molecular mechanism of PRIMA-1.
| MATERIALS AND METHODS

| Cell lines and culture
The human esophageal squamous cell lines TE1, TE4, TE5, TE6,   TE8, TE9, TE10, TE11 and TE14 were 
| Western blot analysis
Total proteins were extracted from cultured cells using RIPA buffer containing protease inhibitor and phosphatase inhibitor (Thermo 
| Xenograft models
Animal studies were conducted in strict accordance with the princi- 
| Statistical analysis
Cell culture experiments were repeated at least 3 times. Statistical analyses were performed using the JMP Pro software program, 
Arg, arginine; Cys, cysteine; Gln, glutamine; Gly, glycine; Ile, isoeucine; Leu, leucine; Met, methionine; Tyr, tyrosine; Val, valine.
[Correction added on 19 January 2018, after first online publication: The spelling of "Misssense" was corrected to "Missense" in Table 1 
| DISCUSSION
In this study, we demonstrated that PRIMA-1 showed significant antitumor effects on all ESCC cells with TP53 missense mutations, inducing massive apoptosis, while ESCC cells with wild-type TP53 or other types of TP53 mutations, including frameshift and nonsense mutations, were relatively resistant to PRIMA-1. This antitumor effect was also confirmed by an in vivo study using the ESCC xenograft model. We further demonstrated that the pro-apoptotic protein Noxa plays an important role in PRIMA-1-mediated apoptosis in ESCC.
The tumor suppressor gene TP53 plays multiple suppressive roles, including apoptosis, cell cycle arrest, senescence, DNA repair, and autophagy, in response to cellular stress. However, this gene is inactivated by mutation in half of all human cancers. 31 Most of the TP53 mutations are missense mutations, resulting in amino acid substitutions in the DNA-binding core domain, and TP53 mutations disrupt p53-specific DNA binding and transcriptional transactivation, leading to the loss of functions as a tumor suppressor. 32 The small molecule PRIMA-1 has been identified in the low molecular weight F I G U R E 3 PRIMA-1 leads to the activation of p53-dependent apoptotic pathways in esophageal squamous cell carcinoma (ESCC) cell lines with TP53 missense mutations. The total levels of the indicated proteins were evaluated by western blot analysis in ESCC cell lines with different TP53 mutation status after treatment with 25 and 50 lmol/L PRIMA-1 for 24-48 h. In TE1, TE8 and TE10 cells with TP53 missense mutations, the expression levels of cleaved PARP and Noxa were increased in a dose-dependent manner, whereas no increase was observed in TE9 with a frameshift mutation, TE14 with a nonsense mutation, and KYSE410, KYSE960 with wild-type TP53
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| 417 compound library to restore mutant p53 to the structure and function of wild-type p53 by targeting the p53 DNA-binding core domain, resulting in the induction of p53-mediated apoptosis. 24, 33 However, the mechanisms underlying how PRIMA-1 induces apoptosis in TP53 mutant cancer cells to change the conformation of p53 mutant protein have not been fully understood.
The present study demonstrated that PRIMA-1 selectively induced apoptosis in ESCC cell lines with TP53 missense mutations, as previously reported in other types of cancer. 24, 25, [33] [34] [35] [36] In addition, PRIMA-1 showed no considerable effect on TP53 frameshift and nonsense mutations, in which the p53 protein was undetected by western blot analysis. A frameshift mutation, in theory, has a more dramatic effect on the polypeptide than missense mutations, despite the deletion of just 1 nucleotide, while a nonsense mutation produces no p53 protein due to the change in 1 nucleotide. Thereby, our results support that PRIMA-1 has the capability of inducing the specific restoration of sequence-specific binding to DNA in p53, similar to that in previous reports. 24, 33 As previous studies have reported that methylene quinuclidinone, the active compound converted from PRIMA-1, binds to cysteine residues in the p53 core domain and stabilizes the wild-type p53 conformation, the protein expression of p53 might be at least necessary for PRIMA-1 to function on TP53 mutant ESCC. 33 However, recent reports have suggested that PRIMA-1 can induce cell death through p53-independent mechanisms. F I G U R E 4 PRIMA-1 preferentially induces apoptosis in esophageal squamous cell carcinoma (ESCC) cell lines with TP53 missense mutations and is mediated primarily through Noxa. A, Western blot analysis of total Noxa and cleaved PARP levels after treatment with PRIMA-1 in ESCC cell lines transfected with either control or Noxa siRNA for 24 h. B, Percentage of Annexin V-positive cells after treatment with PRIMA-1 in ESCC cell lines transfected with either control or Noxa siRNA for 24 h using flow cytometry. C, The growth suppression effect of PRIMA-1 was evaluated in ESCC cell lines transfected with either control or Noxa siRNA using the MTT assay; n = 3-5. Error bars show the standard deviation. P-values refer to the comparison of Noxa siRNA-transfected samples with control siRNA-transfected samples within each cell line. *P < .05, **P < .01, ***P < .001 completely inhibited to the level of non-treatment in TE10. This result might imply that p53-independent pathways also contribute to PRIMA-1-induced apoptosis in TE1, which is supported by previous reports showing that PRIMA-1 induced apoptosis through the upregulation of Noxa in a p53-independent manner in other types of cancer. 25, 28 In this context, we found that the induction of ROS after PRIMA-1 treatment in TE1, but not in TE10, was inhibited by N-acetyl cysteine (data not shown). Because Noxa is upregulated in a ROS-dependent pathway in a p53-independent manner, 41 the PRIMA-1-induced upregulation of Noxa in TE1 could be through a ROS-dependent pathway in addition to a p53-dependent pathway.
In conclusion, the present study showed the first evidence that PRIMA-1 inhibits cell viability and tumor growth specifically in ESCC cells with TP53 missense mutations. We further uncovered the molecular mechanism underlying PRIMA-1-mediated apoptosis through the upregulation of the pro-apoptotic protein Noxa, leading to the activation of cleaved PARP. This significant antitumor effect and its mechanism were also confirmed in an in vivo ESCC xenograft model. Although these results should be validated in the future, PRIMA-1 could be a novel treatment as a potential anticancer agent in clinical trials for ESCC harboring an extraordinarily high frequency of TP53 missense mutation.
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